PURPOSE: Data on encephalitis in elderly patients are scarce. We aimed to describe the characteristics, aetiologies, management, and outcome of encephalitis in patients older than 65 years. METHODS: We performed an ancillary study of ENCEIF, a prospective cohort that enrolled all cases of encephalitis managed in 46 clinical sites in France during years 2016-2019. Cases were categorized in three age groups: (1) 18-64; (2) 65-79; (3)???80 years. RESULTS: Of the 494 adults with encephalitis enrolled, 258 (52%) were???65 years, including 74 (15%)???80 years. Patients???65 years were more likely to present with coma, impaired consciousness, confusion, aphasia, and rash, but less likely to present with fever, and headache (P?<?0.05 for each). Median cerebrospinal fluid (CSF) white cells count was 61/mm(3)[13-220] in 65-79 years, 62 [17-180] in???80 years, vs. 114 [34-302] in?<?65 years (P?=?0.01). The proportion of cases due to Listeria monocytogenes and VZV increased after 65 years (P?<?0.001), while the proportion of tick-borne encephalitis and Mycobacterium tuberculosis decreased with age (P?<?0.05 for each). In-hospital mortality was 6/234 (3%) in?<?65 years, 18/183 (10%) in 65-79 years, and 13/73 (18%) in???80 years (P?<?0.001). Age???80 years, coma on admission, CSF protein???0.8 g/L and viral encephalitis were independently predictive of 6 month mortality. CONCLUSION: Elderly patients represent?>?50% of adults with encephalitis in France, with higher proportion of L. monocytogenes and VZV encephalitis, increased risk of death, and sequels. The empirical treatment currently recommended, aciclovir and amoxicillin, is appropriate for this age group.